P
Patrice Chevallier
Researcher at French Institute of Health and Medical Research
Publications - 431
Citations - 8920
Patrice Chevallier is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 40, co-authored 352 publications receiving 6915 citations. Previous affiliations of Patrice Chevallier include Paris Descartes University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Françoise Huguet,Thibaut Leguay,Emmanuel Raffoux,Xavier Thomas,Kheira Beldjord,Eric Delabesse,Patrice Chevallier,Agnès Buzyn,André Delannoy,Yves Chalandon,Jean-Paul Vernant,Marina Lafage-Pochitaloff,Agnès Chassevent,Véronique Lhéritier,Elizabeth Macintyre,Marie-Christine Béné,Norbert Ifrah,Hervé Dombret +17 more
TL;DR: It is suggested that pediatric-inspired therapy markedly improves the outcome of adult patients with ALL, at least until the age of 45 years, as compared with the previous LALA-94 experience.
Journal ArticleDOI
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Giovanni Martinelli,Nicolas Boissel,Patrice Chevallier,Oliver G. Ottmann,Nicola Gökbuget,Max S. Topp,Adele K. Fielding,Alessandro Rambaldi,Ellen K. Ritchie,Cristina Papayannidis,Lulu Ren Sterling,Jonathan Benjamin,Anthony S. Stein +12 more
TL;DR: Single-agent blinatumomab showed antileukemia activity in high-risk patients with Ph+ ALL who had relapsed or were refractory to TKIs and intolerant or refractor to imatinib.
Journal ArticleDOI
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Kheira Beldjord,Sylvie Chevret,Vahid Asnafi,Françoise Huguet,Marie-Laure Boulland,Thibaut Leguay,Xavier Thomas,Jean-Michel Cayuela,Nathalie Grardel,Yves Chalandon,Nicolas Boissel,Beat W. Schaefer,Eric Delabesse,Hélène Cavé,Patrice Chevallier,Agnes Buzyn,Thierry Fest,Oumedaly Reman,Jean-Paul Vernant,Véronique Lhéritier,Marie C. Béné,Marina Lafage,Elizabeth Macintyre,Norbert Ifrah,Hervé Dombret +24 more
TL;DR: It is indicated that genetic abnormalities are important predictors of outcome in adult ALL not fully recapitulated by early response to therapy, as assessed by immunoglobulin/T-cell receptor minimal residual disease (MRD) levels.
Journal ArticleDOI
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Sébastien Maury,Sylvie Chevret,Xavier Thomas,Dominik Heim,Thibaut Leguay,Françoise Huguet,Patrice Chevallier,Mathilde Hunault,Nicolas Boissel,Martine Escoffre-Barbe,Urs Hess,Norbert Vey,Jean-Michel Pignon,Thorsten Braun,Jean-Pierre Marolleau,Jean-Yves Cahn,Yves Chalandon,Véronique Lhéritier,Kheira Beldjord,Marie C. Béné,Norbert Ifrah,Hervé Dombret +21 more
TL;DR: Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL.
Journal ArticleDOI
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
Lionel Ades,Lionel Ades,Agnès Guerci,Emmanuel Raffoux,Miguel A. Sanz,Patrice Chevallier,Simona Lapusan,Christian Recher,Xavier Thomas,Consuelo Rayon,Sylvie Castaigne,Olivier Tournilhac,Stéphane de Botton,Norbert Ifrah,Jean-Yves Cahn,Eric Solary,Claude Gardin,Nathalie Fegeux,Dominique Bordessoule,Augustin Ferrant,Sandrine Meyer-Monard,Norbert Vey,Hervé Dombret,Laurent Degos,Sylvie Chevret,Pierre Fenaux,Pierre Fenaux +26 more
TL;DR: The 10-year cumulative incidence of deaths in complete response (CR) was 5.7%, 15.4%, and 21.7% in patients younger than 55, 55 to 65, and older than 65 years, respectively, supporting the need for less myelosuppressive treatments, particularly for consolidation therapy.